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Notch signalling controls the differentiation of haemato-
poietic progenitor cells (HPCs). Here, we show that loss of
membrane-type 1 matrix metalloproteinase (MT1-MMP,
MMP14), a cell surface protease expressed in bone marrow
stromal cells (BMSCs), increases Notch signalling in HPCs
and specifically impairs B-lymphocyte development.
When co-cultured with BMSCs in vitro, HPCs differentia-
tion towards B lymphocytes is significantly compromised
on MT1-MMP-deficient BMSCs and this defect could be
completely rescued by DAPT, a specific Notch signalling
inhibitor. The defective B-lymphocyte development could
also be largely rescued by DAPT in vivo. MT1-MMP inter-
acts with Notch ligand Delta-like 1 (Dll1) and promotes its
cleavage on cell surface in BMSCs. Ectopic MT1-MMP
cleaves Dll1 and results in diminished Notch signalling
in co-cultured cells. In addition, recombinant MT1-MMP
cleaves a synthetic Dll1 peptide at the same site where
MT1-MMP cleaves Dll1 on the cell surface. Our data
suggest that MT1-MMP directly cleaves Dll1 on BMSCs
to negatively regulate Notch signalling to specifically
maintain normal B-cell development in bone marrow.
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Introduction
Notch signalling has an important role in regulating
intercellular communication, which is essential for various
biological functions, such as cell fate decision, proliferation,
survival and apoptosis (Artavanis-Tsakonas et al, 1999; Bray,
2006). It is involved in diverse developmental processes of
organs, tissues and cells (Conlon et al, 1995; Radtke et al,
1999; Gaiano et al, 2000; Huppert et al, 2000; Krebs et al,
2000; Morrison et al, 2000; Morrow et al, 2008). In mamma-
lian cells, the Notch signalling pathway is composed of four
receptors (Notch1, 2, 3 and 4) and five ligands (Jagged1 and
2, and Delta-like 1 (Dll1), 3 and 4), which are all expressed on
the cell surface. The binding of ligands to Notch receptors
transmits Notch signalling to neighbouring cells. The inter-
action first triggers a stepwise processing of Notch receptor
and releases the intracellular domain termed Notch intracel-
lular domain (NICD; Schroeter et al, 1998; Brou et al, 2000;
Mumm et al, 2000). Then, NICD translocates into the nucleus
and forms a complex with CSL DNA binding protein
(also known as CBF1 and RBP-Jk) and other co-activators
to transactivate downstream target genes such as Hes1 and
Hes5 (Jarriault et al, 1995; Wu et al, 2000).
The contribution of Notch signalling to early lymphocyte
development has been well described. Notch signalling
favours T-cell commitment from common progenitor cells at
the expense of B-cell development. This has been supported
by various loss or gain of function analyses of Notch pathway
components. For example, Notch1 deletion leads to a block of
thymus T-cell development but promotes abnormal B-cell
commitment (Radtke et al, 1999; Wilson et al, 2001).
Similarly, the deletion of RBP-Jk leads to the same defect of
early lymphocyte development (Han et al, 2002). In addition,
overexpression of activated Notch1 (aNotch1) in haemato-
poietic progenitor cells (HPCs) results in reduction in B-cell
population in bone marrow but promotion of T-cell commit-
ment (Pui et al, 1999). Overexpression of Notch signalling
target genes, the transcription factors Hes5 and Hes1, partially
block B-cell development (Kawamata et al, 2002; Hoebeke
et al, 2006). Furthermore, deletion of the Notch negative
regulator LRF also blocks B-cell development and promotes
T-cell commitment (Maeda et al, 2007). The critical role of
Notch signalling in lymphocyte development is further sup-
ported by a well-established in vitro co-culture system.
Stromal cells overexpressing Notch ligand Dll1 initiate the
T-cell commitment at the expense of B-cell development from
co-cultured HPCs (Jaleco et al, 2001; Schmitt and Zuniga-
Pflucker, 2002).
In mammalian bone marrow, fibroblast-like stromal cells
contribute critically to the development of haematopoietic
cells, including stem cell maintenance and lineage cell devel-
opment, by direct contact or release of cytokines (Nagasawa,
2006). Notch ligands, including Dll1, are expressed by the
stromal cells whereas Notch receptors are widely expressed
on haematopoietic cells (Radtke et al, 2004), suggesting that
Notch signalling is involved in the haematopoietic system.
However, in bone marrow, only B lymphocytes and not Tcells
are generated. These studies indicate that Notch signalling
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might be negatively regulated to maintain normal B-cell
development. The cleavage of Dll1 from the cell surface
is one potential way to inactivate Dll1-induced Notch
signalling. It has been shown that Dll1 is cleaved by
various proteases of the ADAM (A Disintegrin And
Metalloproteinase) family (Six et al, 2003; Dyczynska et al,
2007). The cleavage of Dll1 by ADAM10 impairs Notch
signalling and consequently causes defective self-renewal in
neural precursor cells (Muraguchi et al, 2007).
MT1-MMP, encoded by MMP14, is an important cell
surface metalloproteinase that plays critical roles in matrix
degradation and regulation of receptor signalling. MT1-MMP
is expressed predominantly in bone tissues including bone
marrow. Deficiency in MT1-MMP significantly impairs the
endochondral ossification. However, it is not known if loss of
MT1-MMP affects lymphocyte development. Here, we show
loss of MT1-MMP enhances Notch signalling in HPCs and
partially blocks B-cell development in bone marrow. Purified
bone marrow stromal cells (BMSCs) from MT1-MMP-
deficient mice enhance Notch signalling and inhibit B-cell
commitment in co-cultured HPCs. The defective B-cell devel-
opment could be rescued in vitro and in vivo by a specific
Notch signalling inhibitor. MT1-MMP in BMSCs facilitates
the cleavage of Notch ligand Dll1. In addition, recombinant
MT1-MMP cleaves Dll1 peptide at a novel site different from
that cleaved by ADAMs. These data suggest that MT1-MMP
directly cleaves Dll1 and negatively regulates Dll1-induced
Notch signalling in HPCs, thus specifically modulating
B-lymphocyte differentiation in bone marrow.
Results
Abnormal B-cell development in MT1-MMP-deficient
bone marrow
To investigate whether MT1-MMP is required for early
development of lymphocytes, we collected total bone marrow
from wild-type and MT1-MMP-deficient mice aged day 10–14
to analyse various lymphocyte populations. The percentage
of total B cells, including early stage (B220þCD43þ ) and late
stage (B220þCD43"), was both dramatically declined in
MT1-MMP-deficient mice (Figure 1A and C). The pre-pro B
cells identified as the B220þCD43þ CD24low/" population
and the pro B cells identified as the B220þCD43þ CD24high
population (Nagasawa, 2006) were found to be significantly
reduced in MT1-MMP-deficient bone marrow compared
with that in wild types (Figure 1A–C). Consistently, the
B220þCD19"AA4.1þ early stage B cells and B220þCD19þ
AA4.1þ , B220þCD19þAA4.1" late stage B cells were also
reduced in bone marrow from MT1-MMP-deficient mice
(Supplementary Figure S1). However, both B220þCD19"
AA4.1þ early stage B cells and B220þCD19þAA4.1þ ,
B220þCD19þ AA4.1" late stage B cells in the fetal liver of
MT1-MMP-deficient mice were comparable to that in wild
types (Supplementary Figure S2), suggesting that no signifi-
cant impairment in B-cell development was observed in
MT1-MMP-deficient fetal liver. These data indicate that the
B-cell development defect occurs at relatively early stage
specifically in the bone marrow of MT1-MMP-deficient mice,
suggesting that MT1-MMP is required for the commitment
of bone marrow haematopoietic progenitors to the B-cell
lineage.
We then examined the T-cell populations in bone marrow.
There were small populations of CD4þ single positive T cells
(CD4 SP) and CD8þ single positive T cells (CD8 SP) in either
wild-type or MT1-MMP-deficient bone marrow (Figure 1D
and F). These cells were recruited from the peripheral circu-
lation, because the CD4þCD8þ double positive T cells (DP)
and immature CD4"CD8"CD25þCD44þ T-cell progenitors
(CD25þCD44þ DN) were hardly detectable in bone marrow
of either wild-type or MT1-MMP-deficient mice (Figure
1D–F). The T-cell populations in thymus were also examined.
No significant difference was observed in either CD4 SP, CD8
SP and CD4CD8 DP T-cell populations (Supplementary
Figure S3A and B), or DN1 (CD4"CD8"CD25"CD44þ ),
DN2 (CD4"CD8"CD25þCD44þ ), DN3 (CD4"CD8"CD25þ
CD44") and DN4 (CD4"CD8" CD25"CD44") progenitors
(Supplementary Figure S3C and D), between wild-type and
MT1-MMP-deficient mice. These data suggest that T-cell
commitment in either bone marrow or thymus is not
significantly affected in MT1-MMP-deficient mice.
Abnormal B-cell development in MT1-MMP-deficient
mice may not be cell autonomous
To understand whether the abnormal B-cell development in
MT1-MMP-deficient mice is cell autonomous, bone marrow
reconstitution experiments were performed. Total bone
marrow from either wild-type mice or MT1-MMP-deficient
mice (both of CD45.2 background) was transplanted into
lethally irradiated adult wild-type mice of CD45.1 back-
ground. Six months later, total bone marrow cells were
collected and B-cell populations were analysed. High recon-
stitution efficiencies were achieved, as demonstrated by the
ratio of CD45.2þ cells to total CD45þ cells (Supplementary
Figure S4). In the reconstituted adult mice, two B220þ
populations (B220high and B220low) were observed. It has
been shown that the B220high population represents
the recruited mature B cells. The B220low population repre-
sents the bone marrow-derived lineage B-cell precursors
(Masuzawa et al, 1994). We use the ratio of CD45.2þ
B220low cells to CD45.2þ (CD45.2þB220low plus CD45.2þ
B220" population) cells to measure the differentiation capa-
city of B cells from donor HPCs. The B-cell differentiation in
bone marrow was comparable between recipients reconsti-
tuted with MT1-MMP-deficient bone marrow and recipients
reconstituted with wild-type bone marrow (Figure 2A and B).
There was no significant difference in CD3þ T-cell popula-
tions between wild-type and MT1-MMP-deficient bone mar-
row recipients after bone marrow reconstitution (Figure 2C
and D). These data indicate that the abnormal B-cell devel-
opment in MT1-MMP-deficient mice is likely not resulted
from intrinsic defects in haematopoietic cells, but rather a
consequence of the defective niche, such as the BMSCs.
BMSCs express MT1-MMP
MT1-MMP has been shown to be expressed in mesenchymal
derived osteoblast cells and adipocytes (Kinoh et al, 1996;
Apte et al, 1997; Chun et al, 2006). To understand why loss of
MT1-MMP results in defective B-cell development, we first
examined the expression of MT1-MMP in bone marrow.
Paraffin sections of mouse long bones were prepared and
MT1-MMP expression was assessed by immunohistochemis-
try. The fibroblast-like cells known as bone marrow mesench-
ymal stromal cells were positive for MT1-MMP. The small
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haematopoietic cells in the bone marrow derived from wild-
type mice were negative for MT1-MMP immunostaining. As
expected, the immunostaining was negative in bone marrow
from MT1-MMP-deficient mice (Figure 3A). The expression
of MT1-MMP in purified BMSCs was further confirmed by
western blotting. Total bone marrow cells from long bones
(femurs and tibias) were isolated and cultured for 2 weeks.
The adherent fibroblast-like BMSCs were collected, sorted to
remove contaminated lineage-positive haematopoietic cells
and subcultured in vitro. The isolated BMSCs from both
wild-type and MT1-MMP-deficient mice showed similar
morphology in culture. MT1-MMP was highly expressed in
wild-type BMSCs (Figure 3B and C). Thus, both in vivo and
in vitro results show that MT1-MMP is highly expressed in
mouse BMSCs.
We then examined the expression of MT1-MMP in HPCs.
Lineage-negative Sca1þcKitþ HPCs were sorted out from
total bone marrow of wild-type mice. Western blotting
Figure 1 MT1-MMP deficiency impairs B-cell development in bone marrow. (A) Flow cytometry analyses of early stage and late stage B-cell
populations in either wild-type (WT) or MT1-MMP-deficient (MT1"/") bone marrow. Numbers adjacent to the outlined areas indicate the
percentage of early stage B220þCD43þ cells (right) or late stage B220þCD43" cells (left). (B) Flow cytometry analyses of B cells gated
on B220þCD43þ population by the expression of CD24. Numbers in the plots indicate the percentage of B220þCD43þCD24low/" cells (left) or
B220þCD43þCD24high cells (right). (C) Statistical analyses of different stages of B-cell development in bone marrow; P¼ 0.0004 (pre-pro B),
P¼ 0.0004 (pro B), Po0.0001 (B220þCD43" B), Po0.0001 (total B), Student’s t-test. Data are representative of three independent experiments
(mean±s.d.). (D) Flow cytometry analyses of bone marrow T cells. Numbers in the plots indicate the percentage of CD4 SP (bottom-right),
CD8 SP (up-left), DP (up-right) and DN (bottom-left) cells. (E) Flow cytometry analyses of bone marrow CD44þCD25þ DN T-cell progenitors.
Numbers in the plots indicate the percentage of CD44þCD25þ DN cells (up-right). (F) Statistical analyses of T-cell populations in bone
marrow; P40.05, Student’s t-test. Data are representative of two independent experiments (mean±s.d.). DP, CD4CD8 double positive;
DN, CD4CD8 double negative; CD4 SP, CD4 single positive; CD8 SP, CD8 single positive.
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showed no detectable MT1-MMP in either sorted HPCs
(Figure 3B) or B220þ B lymphocytes isolated from bone
marrow (Figure 3C). Therefore, MT1-MMP is expressed in
BMSCs but not in haematopoietic cells—at least not in HPCs
or B cells. These data are in line with the observation that the
defect in B-cell development in MT1-MMP-deficient mice is
not cell autonomous.
Notch1 signalling is abnormally increased in MT1-MMP-
deficient haematopoietic progenitors and committed
B lineage cells
To understand the underlying mechanism of defective B-cell
development in bone marrow from MT1-MMP-deficient mice,
we analysed the potential signalling alterations caused by
MT1-MMP deletion. Previous studies have shown that Notch
signalling has a critical role in early lymphocyte commitment.
Activation of Notch signalling in haematopoietic progenitors
blocks B-cell development and induces abnormal T-cell com-
mitment in bone marrow (Pui et al, 1999). It is not surprise
that no abnormal T-cell initiation is observed in MT1-MMP-
deficient bone marrow as it has been shown that a much
higher level of Notch signalling is required to induce T-cell
development than to block B-cell development (Schmitt et al,
2004). In addition, overexpression of either Hes1 or Hes5
partially blocks B-cell development without affecting T-cell
maturation (Kawamata et al, 2002). Therefore, it is possible
that abnormal Notch signalling in MT1-MMP-deficient bone
marrow may be sufficient to affect B-cell development but not
to the level affecting T-cell commitment. To test whether the
defective B-cell development in MT1-MMP-deficient mice is a
consequence of abnormal Notch signalling, the lineage-nega-
tive Sca1þcKitþ HPCs were isolated from both wild-type and
MT1-MMP-deficient bone marrow for Notch signalling
analyses. The aNotch1 (the released intracellular domain of
Notch1) signalling was significantly increased in the HPCs
from MT1-MMP-deficient mice, compared with that from
wild-type mice (Figure 4A). Consistently, the mRNA level of
Notch target Hes5, which could block B-cell development
(Kawamata et al, 2002), was significantly upregulated
in MT1-MMP-deficient HPCs, though the mRNA levels of
Notch target Hes1 and Notch regulator Dtx1 (Deltex1) were
not much affected (Figure 4B). In addition, significant
upregulation of aNotch1 was found in B220þ cells in
MT1-MMP-deficient mice, compared with that in wild-type
mice (Figure 4C). These results indicate that loss of
MT1-MMP enhances Notch1 signalling, which in turn impairs
B-cell development in bone marrow.
MT1-MMP-deficient BMSCs impairs B-cell development
due to increased Notch signalling
Since B-cell development defect in MT1-MMP-deficient mice
might be resulted from altered BMSCs functions (Figures 2A
and B and 3), we cultured wild-type HPCs on wild-type and
MT1-MMP-deficient BMSCs to examine Notch signalling in
the HPCs. Significantly higher levels of aNotch1 protein and
Hes5 mRNA were found in HPCs co-cultured on MT1-MMP-
deficient BMSCs (Figure 5A and B). These results support the
idea that MT1-MMP in stromal cells is required to inhibit
Notch signalling in HPCs. To further investigate whether the
defective B-cell development in MT1-MMP-deficient mice is a
consequence of enhanced BMSCs-mediated Notch signalling,
an in vitro co-culture system was employed to examine the
Figure 2 Reconstitution of either wild-type or MT1-MMP-deficient
bone marrow cells into lethally irradiated wild-type mice. (A) Flow
cytometry analyses of bone marrow B cells 6 months after bone
marrow reconstitution. Numbers in the plots indicate the percen-
tage of CD45.2þB220low cells (up) or CD45.2þB220" cells (bot-
tom). (B) Statistical analysis of B-cell commitment from donor bone
marrow cells after bone marrow reconstitution; P40.05, Student’s
t-test. Data are representative of two independent experiments
(mean±s.d.). (C) Flow cytometry analyses of bone marrow
T cells 6 months after bone marrow reconstitution. Numbers in
the plots indicate the percentage of CD45.2þCD3þ cells (up) or
CD45.2þCD3" cells (bottom). (D) Statistical analysis of T-cell
commitment from donor bone marrow cells after bone marrow
reconstitution; P40.05, Student’s t-test. Data are representative
of two independent experiments (mean±s.d.).
Figure 3 MT1-MMP is expressed in BMSCs but not in HPCs.
(A) Immunostaining analyses of MT1-MMP in wild-type bone
marrow section. MT1"/" bone marrow section serves as negative
control. Arrows indicate fibroblast-like stromal cells. (B, C)
Immunoblot analyses of MT1-MMP expression in BMSCs, HPCs
and B cells. MT1"/" BMSCs serve as negative control. b-Actin
serves as an internal loading control.
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differentiation of HPCs. Lineage-negative Sca1þcKitþ HPCs
were cultured on top of the BMSCs for 7 days before the
commitment into B cells was analysed. A significantly lower
percentage of B-cell commitment was found from HPCs
cultured on MT1-MMP-deficient BMSCs, compared with
those cultured on wild-type BMSCs. When Notch signalling
was inhibited by DAPT in the co-culture system, the defective
B-cell development from HPCs cultured on MT1-MMP-defi-
cient BMSCs was restored (Figure 5C and D), suggesting that
defective B-cell development mediated by BMSCs in MT1-
MMP-deficient bone marrow is Notch signalling dependent.
However, similar to the in vivo data, CD3þ T-cell population
was not observed in the co-culture system (Figure 5C).
Further examination of the T-cell commitment after 2 weeks
co-culture revealed that neither late stage T cells (CD4 SP
and CD8 SP), nor earlier T-cell progenitors (CD4CD8 DP
and CD25þCD44þ DN) were detectable (Figure 5E and F),
suggesting that enhanced Notch signalling mediated by MT1-
MMP-deficient BMSCs specifically impairs B-cell develop-
ment, but is not sufficient to promote T-cell development
(Schmitt et al, 2004).
To substantiate the observation that lack of MT1-MMP in
BMSCs can increase the transmission of Notch signalling, we
employed a well-characterized co-culture system in which the
differentiation of C2C12 myoblasts into myotubes is inhibited
by Notch signalling (Shawber et al, 1996; Nofziger et al, 1999;
Lehar et al, 2005). The C2C12 cells were co-cultured on either
wild-type or MT1-MMP-deficient BMSCs to induce myotube
formation in vitro. The g-secretase inhibitor DAPT was used
to inhibit Notch signalling. Significantly reduced myotube
formation was observed in C2C12 cells cultured on MT1-
MMP-deficient BMSCs (Figure 6A). The mRNA levels of both
Mlc2 and Myog detected by real-time qPCR were decreased
significantly in C2C12 co-cultured on MT1-MMP-deficient
BMSCs, compared with that on wild-type BMSCs
(Figure 6B). Mlc2 and Myog were expressed in differentiated
C2C12 cells but not in BMSCs (Figure 6C). When Notch
signalling was inhibited by DAPT, defective myotube forma-
tion in C2C12 cells co-cultured on MT1-MMP-deficient
BMSCs was rescued (Figure 6A). The decreased mRNA levels
of Mlc2 and Myog in C2C12 cells co-cultured on MT1-MMP-
deficient BMSCs were partially rescued by low concentration
of DAPT (1 mM), and completely rescued by high concentra-
tion of DAPT (10mM) (Figure 6B), suggesting that the inhibi-
tory effect of MT1-MMP-deficient BMSCs on myotube
formation is indeed through Notch signalling. These data
further confirm that loss of MT1-MMP activity significantly
enhances Notch signalling in neighbouring cells.
Rescuing impaired bone marrow B-cell development
in MT1-MMP conditional knockout mice by Notch
signalling inhibitor
To investigate if defective B-cell development in MT1-MMP-
deficient mice could be rescued by Notch signalling
inhibition, the conditional MT1-MMP-deficient mice were
established. (The establishment of conditional MT1-MMP-
deficient mice will be reported separately elsewhere.)
Prx1Cre transgenic mice were used to delete MT1-MMP in
BMSCs (Logan et al, 2002; Hilton et al, 2008) (Figure 7A).
The MT1flox/flox Prx1Creþ mutant mice survived at least one
and a half year. The MT1-MMP protein is nearly completely
depleted in the MT1flox/flox Prx1Creþ BMSCs compared with
that in the control MT1flox/flox BMSCs (Figure 7B). The B-cell
populations in adult mice were then analysed. Consistent
with that in MT1-MMP total deficient bone marrow, both
early stage (B220lowCD43þ CD24low/", B220lowCD43þ
CD24high) and late stage (B220lowCD43") B cells were redu-
ced in MT1flox/flox Prx1Creþ bone marrow (Figure 7D–F).
MT1-MMP conditional deficient mice (MT1flox/flox Prx1Creþ )
were then received DAPT treatment subcutaneously for
4 weeks. The mRNA level of Hes5 in HPCs from mock-treated
MT1flox/flox Prx1Creþ bone marrow was much higher than
that from control (MT1flox/flox) bone marrow, DAPT treatment
at concentration of 100mg/kg body weight significantly
reduced Hes5 transcription, though still higher than that in
control (Figure 7C). The reduction in B-cell populations in
the conditional deficient bone marrow was largely rescued by
Notch inhibitor DAPT, though not to the level similar to that
in controls (Figure 7D–F). This is likely due to the incomplete
inhibition of Notch reflected by the Hes5 transcription in
HPCs (Figure 7C). These in vivo data further support that
defective B-cell development in MT1-MMP-deficient bone
marrow is attributable, largely if not all, to abnormally
enhanced Notch signalling.
MT1-MMP cleaves Dll1 to inhibit Notch1 signalling
Notch signalling has the unique property that it can be
transactivated by the ligands expressed on the surface of
neighbouring cells. The enhancement of Notch signalling in
HPCs mediated by MT1-MMP-deficient BMSCs might be
explained by the increased Notch ligands on the stromal
cell surface. Among the five mammalian Notch ligands,
Dll1 has been previously shown to induce Notch signalling,
leading to blockage of B-cell development (Schmitt and
Zuniga-Pflucker, 2002). The cleavage of Dll1 inhibits Notch
signalling (Muraguchi et al, 2007). Similar to Dll1, the
metalloproteinase MT1-MMP is also expressed on membrane,
Figure 4 Loss of MT1-MMP increases Notch1 signalling in either HPCs or B cells. (A) Immunoblot analyses of aNotch1 in isolated lineage-
negative Sca1þcKitþ HPCs. (B) Real-time PCR analyses of mRNA levels of Hes1, Hes5 and Dtx1 in isolated HPCs from wild-type and
MT1-MMP"/" bone marrow; P¼ 0.0011 (Hes5), Student’s t-test. Data are representative of three independent experiments (mean±s.d.).
(C) Immunoblot analyses of aNotch1 in isolated B220þ B cells. b-Actin serves as an internal loading control (A, C).
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raising the possibility that MT1-MMP might promote the
cleavage of Dll1 in BMSCs to inhibit Notch signalling in
neighbouring HPCs. To test this hypothesis, we first examined
the interaction between MT1-MMP and Dll1 in BMSCs and
found that these two proteins were co-immunoprecipitated
each other (Figure 8A). In addition, the full-length Dll1 (Dll1-
FL) was significantly less in the wild-type BMSCs cells than
that in the MT1-MMP-deficient BMSCs, while there was an
increased accumulation of an B30-kDa C-terminal fragment
of Dll1 (Dll1-CTF) in the wild-type BMSCs (Figure 8B;
Supplementary Figure S5A), suggesting that MT1-MMP pro-
motes the cleavage of Dll1 in BMSCs. Knocking-down of
MT1-MMP in wild-type BMSCs again resulted in significantly
reduced Dll1-CTF and increased full-length Dll1 (Figure 8B;
Supplementary Figure S5A). Jagged1 (Jag1), another Notch
ligand reported to be expressed in BMSCs, was examined and
no difference were found between wild-type and MT1-MMP-
deficient BMSCs (Figure 8C). Dll4 is highly expressed in
thymus epithelial cells and affects the T-cell development in
the thymus (Hozumi et al, 2008; Koch et al, 2008). However,
Figure 5 MT1-MMP-deficient BMSCs partially block B-cell development in vitro in a Notch signalling-dependent manner. (A) Immunoblot
analyses of aNotch1 in lineage-negative Sca1þcKitþ HPCs co-cultured on MT1-MMP"/" BMSCs compared with those co-cultured on wild-type
BMSCs. aNotch1 in the wild-type HPCs without in vitro culture is used as a control. b-Actin serves as an internal loading control. (B) Real-time
PCR analyses of mRNA levels of Hes1 and Hes5 in HPCs co-cultured on MT1-MMP"/" BMSCs compared with those co-cultured on wild-type
BMSCs; P¼ 0.0091 (Hes5), Student’s t-test. Data are representative of three independent experiments (mean±s.d.). (C) Flow cytometry
analyses of lymphocyte commitment from lineage-negative Sca1þcKitþ HPCs co-cultured on either wild-type BMSCs or MT1"/" BMSCs. Both
are treated with either DMSO or Notch inhibitor DAPT. (D) Statistical analyses of B-cell commitment from co-cultured HPCs in (C); P-values,
Student’s t-test. Data are representative of two independent experiments (mean±s.d.). (E, F) Flow cytometry analyses of T-cell commitment
from lineage-negative Sca1þcKitþ HPCs co-cultured on either wild-type or MT1-MMP-deficient BMSCs. Both are treated with either DMSO or
Notch inhibitor DAPT. Numbers in the plots indicate CD4 SP (bottom-right), CD8 SP (up-left), CD4CD8 DP (up-right) and DN (bottom-left) cells
in (E) or CD25þCD44þ DN T-cell progenitors (up-right) in (F).
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its expression was not detectable in BMSCs. Furthermore,
Dll4 was not cleaved by MT1-MMP when they were
co-expressed (Figure 8F).
We then ectopically expressed wild-type human MT1-MMP
(MT1FL) and active-site mutant MT1-MMP (MT1EA), respec-
tively, in HEK293 cells together with mouse Dll1. As shown in
Figure 8D, expression of wild-type MT1-MMP resulted in
reduced full-length Dll1 and increased Dll1-CTF fragment,
compared with that in cells expressing mutant MT1-MMP
(Figure 8D). To further demonstrate that the increased clea-
vage of Dll1 mediated by MT1-MMP would lead to inactiva-
tion of Notch signalling in neighbouring cells, we established
a 293 cell line stably expressing human Notch1 (293hN1) and
HeLa cell lines that ectopically express either wild-type
or activity-mutated MT1-MMP, together with Dll1. Similar
to our observations in HEK293 cells, an increased cleavage
of Dll1 was observed in HeLa cells expressing wild-type MT1-
MMP, compared with that in HeLa cells expressing mutant
MT1-MMP. When 293hN1 cells were seeded on top of HeLa
cells expressing MT1-MMP and Dll1, significantly reduced
Notch1 signalling was observed in 293hN1 cells co-cultured
with HeLa cells expressing wild-type MT1-MMP, compared
with that in 293hN1 cells co-cultured with HeLa cells expres-
sing mutant MT1-MMP (Figure 8E). These results further
demonstrate that MT1-MMP can promote the cleavage of
the Notch ligand Dll1 and the enhanced cleavage of Dll1
mediated by MT1-MMP inhibits Notch signalling in neigh-
bouring cells. Thus, lack of MT1-MMP diminishes the lateral
inhibitory effect and leads to enhanced Notch signalling
in neighbouring cells. This explains the abnormal B-cell
development in bone marrow of MT1-MMP-deficient mice,
even though neither HPCs nor B cells expresses MT1-MMP.
The cleavage of Dll1 produces an B30-kDa C-terminal
fragment, similar to that cleaved by ADAMs (Six et al,
2003). It has been suggested that the cleavage site of Dll1
by ADAM10 is at H-536M. To determine if MT1-MMP cleaves
Dll1 directly, we synthesized a Dll1 polypeptide (516QFLLPEP
PPGPMVVDLSERHMESQGGPFP) containing ADAM10
cleavage site H-536M and incubated it with the recombinant
catalytic form of MT1-MMP. Mass spectrometry analyses of
the reaction products showed a fragment at 2015.9Da
(Supplementary Figure S6A). Its amino-acid sequence was
further identified as 527MVVDLSERHMESQGGPFP by tandem
MS/MS (Supplementary Figure S6B), suggesting that
MT1-MMP can cleave Dll1 directly at P-527M. This cleavage
site is different from that by ADAM10. We then purified the
B30-kDa C-terminal fragment from HEK293 cells expressing
both wild type MT1-MMP and Dll1 for N-terminal sequencing
by Edman degradation. Again, a Dll1 fragment started
from 527M was identified (Supplementary Figure S7A
and B), confirming the existence of a novel Dll1 cleavage
site at P-527M by MT1-MMP. We also identified the Dll1
Figure 6 MT1-MMP-deficient BMSCs inhibit myotube formation of C2C12 cells in a Notch signalling-dependent manner. (A) Myotube
formation analyses of C2C12 myoblasts co-cultured on either wild-type or MT1-MMP"/" BMSCs are shown. Both are treated with either DMSO
or Notch inhibitor DAPT. Pictures are taken after 2 weeks of differentiation induction with a lower concentration of horse serum. Original
magnification, $ 200. (B) Real-time PCR analyses of Mlc2 and Myog mRNA levels in the C2C12 cells co-cultured on either wild-type or
MT1-MMP"/" BMSCs, treated with either DMSO or different dose of DAPT. Data are representative of two independent experiments
(mean±s.d.). (C) Semi-quantitative RT–PCR analyses of Mlc2 and Myog expression in C2C12 cells prepared in (A) and BMSCs with the
same culture condition.
MT1-MMP cleaves Dll1 to regulate Notch signalling
G Jin et al
&2011 European Molecular Biology Organization The EMBO Journal VOL 00 | NO 00 | 2011 7
fragment started from 536M, which is likely produced by
endogenous ADAMs.
Discussion
MT1-MMP is a membrane-bound matrix metalloproteinase
first identified on the surface of invasive tumour cells as an
activator of proMMP2 (Sato et al, 1994). MT1-MMP
contributes to the degradation of various extracellular matrix
(ECM) components and thus promotes invasion and migra-
tion (Seiki and Yana, 2003). However, the role of MT1-MMP is
broader than simply degradation of ECM components. It has
also been shown to cleave membrane receptors and ligands
and consequently regulate intracellular signal transduction
(Lehti et al, 2005, 2009). Here, we show that MT1-MMP
cleaves Dll1 in BMSCs to inhibit Dll1-induced Notch signal-
ling in neighbouring HPCs, and thus maintains normal B-cell
development in bone marrow (Figure 9).
Notch signalling provides direct cell–cell communication
through ligand–receptor interaction-mediated signalling
transduction. The wide expression of Notch ligands on
stromal cells and receptors on haematopoietic cells indicates
an important function of Notch signalling in haematopoiesis
(Radtke et al, 2004). Indeed, Notch signalling has been
shown to promote T-cell development but block B-cell
development through gain of function studies in vivo and
in vitro (Pui et al, 1999; Schmitt and Zuniga-Pflucker, 2002).
However, in bone marrow, only B lymphocytes are generated,
indicating that bone marrow Notch signalling is not sufficient
to initiate T-cell commitment. In addition, loss of function in
Notch signalling does not disturb bone marrow lineage
development (Radtke et al, 1999), suggesting that proper
level of Notch signalling in bone marrow is critical in main-
taining B-cell development. Notch signalling is also essential
for the formation of embryonic haematopoietic stem cells
(HSCs; Kumano et al, 2003; Robert-Moreno et al, 2008). Gain
of function analyses, including activating Notch signalling
in vivo or treating HSCs with ligands in vitro, support the idea
that Notch signalling promotes survival and self-renewal of
HSCs (Varnum-Finney et al, 1998; Karanu et al, 2000, 2001;
Stier et al, 2002; Burns et al, 2005; Suzuki et al, 2006).
However, inactivation of Notch signalling, by either over-
expressing dominant-negative Mastermind-like 1 or deletion
of RBP-Jk in vivo, does not impair the maintenance of HSCs
(Maillard et al, 2008). These findings collectively indicate
that negative regulation mechanisms exist to maintain Notch
Figure 7 Rescuing impaired bone marrow B-cell development in MT1-MMP conditional deficient mice by Notch signalling inhibitor. (A)The
strategy to breed MT1-MMP conditional deficient MT1flox/flox Prx1Creþ mice. (B) Immunoblot analyses of MT1-MMP in BMSCs purified from
MT1-MMP conditional deficient mice and littermate controls. (C) Real-time PCR analyses of Hes5mRNA level in isolated HPCs fromMT1-MMP
conditional deficient mice and littermate controls, treated with either Notch inhibitor DAPTor solvent only. (D, E) Flow cytometry analyses of
bone marrow B-cell populations in MT1-MMP conditional deficient and littermate control mice treated with either DAPT or solvent only.
Numbers adjacent to the outlined areas in (D) indicate the percentage of early stage B220þCD43þ cells (right) or late stage B220þCD43" cells
(left). Numbers in the plots in (E) indicate the percentage of B220þCD43þCD24low/" cells (left) or B220þCD43þCD24high cells (right).
(F) Statistical analyses of B-cell populations in MT1-MMP conditional deficient mice and littermate controls, treated with DAPTor solvent only.
Data are representative of two independent experiments (mean±s.d.). Five to six mice are analysed for each group.
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signalling at a relatively low level in bone marrow. Previous
study has demonstrated that LRF negatively regulates Notch
signalling in bone marrow cells (Maeda et al, 2007). Here, we
show that loss of MT1-MMP on BMSCs results in defective
cleavage of Dll1, resulting in increased Notch1 signalling in
HPCs, and consequently partially blocks B-cell development.
The defective B-cell differentiation co-cultured on MT1-MMP-
deficient BMSCs can be completely rescued by Notch signal-
ling inhibitor DAPT, demonstrating that the defective B-cell
differentiation is Notch signalling dependent. Importantly,
defective B-cell development was largely rescued by DAPT
treatment in vivo, suggesting that indeed defective B-cell
differentiation in MT1-MMP-deficient mice is attributable to
abnormal Notch signalling mediated by compromised Dll1
cleavage on BMSCs. Notably, the treatment did not result in a
completely rescue in B-cell development. This is likely due to
that dosage of DAPT used is not optimal reflected by the
incompletely inhibition of Hes5 expression. We could not
exclude the possibility that other unidentified abnormality in
niche may also contributes, to certain extend, to the defective
B-cell differentiation in MT1-MMP-deficient mice. The nega-
tive regulation of Notch signalling by MT1-MMP is further
demonstrated by Notch signalling-dependent inhibition of
C2C12 differentiation in a well-defined co-culture system in
which defective myotube formation and decreased muscle-
specific gene expressions of Myog and Mlc2 in C2C12 on
MT1-MMP-deficient BMSCs are completely rescued by DAPT.
The enhanced Notch signalling resulted from MT1-MMP
Figure 8 MT1-MMP promotes the cleavage of Notch ligand Dll1. (A) MT1-MMP interacts physically with Dll1. Co-immunoprecipitation of
MT1-MMP and Dll1 in wild-type BMSCs. Left panel shows immunoblot analyses of MT1-MMP and Dll1 precipitated by Dll1 antibodies. Right
panel shows immunoblot analyses of MT1-MMP and Dll1 precipitated by MT1-MMP antibodies. IgG precipitation serves as the negative control
in both cases. (B) Immunoblot analyses of Dll1 in wild-type and MT1-MMP-deficient BMSCs. The cleavage of Dll1 is also analysed in wild-type
BMSCs in which MT1-MMP is knocked down by siRNA. In both wild-type BMSCs and MT1-MMP-deficient BMSCs, Dll1 is knocked down to
confirm the specific bands for Dll1. Dll1-FL represents unprocessed full-length Dll1 and Dll1-CTF represents C-terminal cleaved fragment of
Dll1. (C) Immunoblot analyses of Jag1 in wild-type and MT1-MMP-deficient BMSCs. (D) Immunoblot analyses of Dll1 in HEK293 cells
ectopically expressing Dll1 together with either wild-type MT1-MMP (293MT1FLþDll1) or activity-mutated MT1-MMP (293MT1EAþDll1).
(E) Immunoblot analyses of aNotch1 in 293hN1 cells co-cultured on top of the HeLa cells expressing Dll1 together with either wild-type
MT1-MMP (HeLaMT1FLþDll1) or activity-mutated MT1-MMP (HeLaMT1EAþDll1). (F) Immunoblot analysis of Dll4 in HEK293 cells
ectopically expressing Dll4 together with either wild-type MT1-MMP (293MT1FLþDll4) or activity-mutated MT1-MMP (293MT1EAþDll4).
a-Tubulin (B–E) or b-actin (B, E, F) serves as internal loading controls.
Figure 9 Schematic model illustrating the role of MT1-MMP in
bone marrow B-cell development. The thick solid lines indicate
the known effects of Notch signalling in B-cell development. The
thick broken lines indicate the effects of MT1-MMP in Notch
signalling through the cleavage of Dll1 and consequent B-cell
development proposed in our paper. HSC indicates haematopoietic
stem cells. CLP indicates common lymphoid progenitors. HPC
indicates haematopoietic progenitor cells. BMSC indicates bone
marrow stromal cell.
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deficiency is due to the impaired processing of Dll1 on the cell
surface and MT1-MMP activity is required for the efficient
processing of Dll1. Importantly, recombinant MT1-MMP
cleaves Dll1 peptide at the same site where MT1-MMP
cleaves Dll1 on cell surface identified by N-terminal Edman
sequencing. Thus, MT1-MMP-mediated Dll1 cleavage on
stromal cells has an important role in the negative regulation
of Notch signalling in bone marrow.
The T-cell development in MT1-MMP-deficient bone
marrow is not significantly affected. Previous studies have
shown that the threshold of Notch signalling to promote
T-cell development is higher than that to block B-cell devel-
opment (Schmitt et al, 2004). Therefore, it is likely that the
increased Notch signalling resulted from the MT1-MMP
deficiency is not sufficient to initiate T-cell development,
though sufficient to affect B-cell differentiation. It is unclear
why the enhancement of Notch signalling in MT1-MMP-
deficient mice is mild. One possibility is due to the moderate
level of Dll1 expression in BMSCs. In addition, Dll1 is
cleaved by some membrane metalloproteinases other than
MT1-MMP, such as ADAM9 and ADAM10 (Six et al, 2003;
Dyczynska et al, 2007). Both of them are expressed in BMSCs
(Supplementary Figure S8). This is consistent with the
existence of Dll1-CTF in MT1-MMP-deficient BMSCs
(Figure 8B). The cleavage by ADAMs may partially compen-
sate for the loss of MT1-MMP and minimize the activation of
Notch signalling in MT1-MMP-deficient mice. Furthermore,
the negative regulation of LRF on Notch signalling may also
reduce the enhancement of Notch signalling in MT1-MMP-
deficient mice. However, LRF is not able to completely
suppress the enhanced Notch signalling in MT1-MMP-defi-
cient mice. It is worth of further investigation whether the
function of LRF is disturbed in MT1-MMP-deficient mice.
The T-cell development in thymus is normal and the
protein level of aNotch1 in thymus is comparable between
wild-type and MT1-MMP-deficient mice (Supplementary
Figure S9A), indicating that Notch signalling is not affected
by MT1-MMP in the thymus. This is in line with the fact
that expression of MT1-MMP is minimal in thymus. Similarly,
it may also explain the normal B-cell populations and
unaltered aNotch1 level in MT1-MMP mutant fetal liver
(Supplementary Figure S9B). These data indicate that MT1-
MMP may affect B-cell development specifically through
bone marrow niches.
B cells are derived from bone marrow HSCs through a
serial stage of intermediate progenitor cells. The primitive
HSCs have been reported to locate in different bone marrow
microenvironment niches, composed of blood vessels, osteo-
blasts or stromal cells (Kiel et al, 2005; Sugiyama et al, 2006).
To differentiate into B cells, the intermediate HPCs are
recruited to BMSCs (Tokoyoda et al, 2004) where MT1-
MMP is highly expressed. MT1-MMP is also expressed in
osteoblasts, endothelial cells and vascular smooth muscle
cells (Kinoh et al, 1996; Lehti et al, 2005; Yana et al, 2007),
indicating that MT1-MMP may also affects the osteoblastic
niches and vascular niches of HSCs. However, the HSCs
population in MT1-MMP-deficient bone marrow is normal
(data not shown), suggesting that the maintenance of HSCs
population might not be affected by MT1-MMP deficiency-
triggered Notch signalling enhancement. Similarly, the
deficiency of LRF in bone marrow also results in enhanced
Notch signalling but normal population of HSCs
(Maeda et al, 2007). It is not clear whether much higher
Notch signalling is required to disturb the maintenance
of HSCs, though it seems to be the case for T-lymphocyte
commitment in bone marrow.
The increased Notch signalling in MT1-MMP-deficient
mice does not result in overall phenotypes similar to that
observed in transgenic mice overexpressing aNotch1. This
could be due to the restrict expression of MT1-MMP. Similar
phenotypes may only be observed in tissues where both
MT1-MMP and Notch signalling are prominently expressed.
In addition, the level of Notch signalling may also be
responsible for the difference in the phenotypes between
MT1-MMP-deficient mice and aNotch1 transgenic mice.
Our data suggest that MT1-MMP directly cleaves Notch
ligand Dll1 in BMSCs. The cleavage produces an B30-kDa
C-terminal fragment of Dll1, a size similar to the Dll1 cleaved
by ADAMs (Six et al, 2003; Dyczynska et al, 2007).
Recombinant MT1-MMP directly cleaves Dll1 peptide at the
site close to but different from that cleaved by ADAMs.
Interestingly, Dll1-CTF can be found in MT1-MMP-deficient
BMSCs though much less compared with that in wild-type
BMSCs (Figure 8B), suggesting that at least in BMSCs, MT1-
MMP is the major negative regulator of Dll1-mediated Notch
signalling. As Jagged1 is not affected by MT1-MMP and Dll4
is undetectable by RT–PCR in MT1-MMP-deficient BMSCs,
the enhanced Notch signalling in MT1-MMP-deficient HPCs
is mostly attributable to the defective cleavage of Dll1 in
BMSCs. In conclusion, MT1-MMP is required specifically for
B-lymphocyte development by fine-tuning Notch signalling
in HPCs through regulating Notch ligand Dll1 on BMSCs. The
regulation of Notch signalling by MT1-MMP is tissue depen-
dent. Our data not only demonstrate for the first time that
MT1-MMP negatively modulates Notch signalling to maintain
normal B-lymphocyte development but also provide new
insights into various developmental processes regulated
by the interplay between MT1-MMP and Notch signalling.
Materials and methods
Mice and cell culture
MT1-MMP-deficient mice were established previously (Zhou et al,
2000). Sex matched littermates sacrificed at 10–14 days old were used
for all experiments. To generate mouse BMSCs, total bone marrow
cells were isolated from long bones (both femur and tibia) and
cultured in aMEM medium supplemented with 9% fetal bovine
serum (FBS; Gibco) and 9% horse serum (HS; Hyclone) (Peister et al,
2004). Medium was replaced every 3–4 days to remove non-adherent
haematopoietic cells. After 2 weeks, the adherent cells were collected
and sorted with a mouse lineage kit (BD Bioscience) and anti-biotin
magnetic beads (Miltenyi Biotech). The sorted BMSCs were cultured
in fresh medium and further subcultured. The first passage of
sorted BMSCs was termed passage 1. BMSCs between passages 7 and
12 were used for experiments unless otherwise stated.
DNA constructs
The original human MT1-MMP cDNA was kindly given by Dr Pei
(University of Minnesota). The MT1-MMP cDNA was subcloned
into pTracer-CMV vector (Invitrogen). The construct expressing
inactive MT1-MMP was made through mutating E240 to A. The full-
length mouse Dll1 cDNAwas obtained by PCR from a mouse BMSC
cDNA library and cloned into pcDNA3.1 vector tagged with Flag at
the C-terminus. The human Notch1 cDNA was obtained from
Artavanis-Tsakonas Laboratory (Havard Medical School).
Flow cytometry analysis
Total bone marrow cells were isolated from long bones and stained
with fluorescence-conjugated antibodies in HBSS supplemented
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with 2% FBS. The cells were fixed and the red blood cells were
lysed using BD FACS lysing solution (BD Bioscience) after staining
and then processed for flow cytometry analyses. In vitro cultured
cells were collected and stained with fluorescence-conjugated
antibodies in HBSS supplemented with 2% FBS. The cells were
either fixed with 4% (wt/vol) paraformaldehyde or directly
processed for flow cytometry after staining. FITC anti-CD45.2
(109805), PE/Cy5 anti-B220 (103210), PE anti-CD3 (100205), FITC
anti-CD4 (100406), PE/Cy5 anti-CD8 (100710) and PE anti-CD44
(103023) were purchased from BioLegend. PE anti-CD43 (553271),
FITC anti-CD24 (553261) and FITC anti-CD25 (558689) were
purchased from BD Pharmingen.
Bone marrow reconstitution
Total bone marrow cells were isolated from the MT1-MMP-deficient
mice and comparable wild-type mice with CD45.2 background. The
cells were transplanted into lethally irradiated adult mice with CD45.1
background. After 2 months, the transplantation efficiency was
examined by flow cytometry analysis of donor CD45.2 cells and
recipient CD45.1 cells. Six months later, lymphocyte development was
examined by flow cytometry analysis after the bone marrow cells
were stained with FITC anti-CD45.2, PE/Cy5 anti-B220, and PE anti-
CD3. FITC anti-CD45.1 (110705) was purchased from BioLegend.
Immunoblot analysis
Cells were lysed in a lysis buffer composed of 50mM Tris–HCL (pH
7.5), 150mM NaCl, 1% Nonidet P40, 0.5% sodium deoxycholate
and protease inhibitor cocktail (Roche). Protein lysate was mixed
with loading buffer, separated by SDS–PAGE and then analysed by
immunoblot analysis. Monoclonal anti-MT1-MMP (ab51074) was
purchased from Abcam. Polyclonal anti-cleaved Notch1 (2421) was
purchased from Cell Signaling. Polyclonal anti-Dll1 (sc-8155 and
sc-9102) was purchased from Santa Cruz. Monoclonal anti-Flag
(F1804), monoclonal anti-b-actin (A5316) and monoclonal anti-a-
tubulin (T5168) were purchased from Sigma.
Semi-quantitative RT–PCR and real-time PCR analysis
Total RNAwas extracted from cells, and single complementary DNA
(cDNA) was synthesized using Promega M-MLV reverse transcrip-
tase (M170A). After mixing with specific primers, dNTP and
Finnzymes DNA polymerase (F501L), semi-quantitative PCR was
performed with ABI 9700 PCR system. To perform Real-time PCR,
cDNA was mixed with specific primers and ABI Power SYBR Green
PCR Master Mix (4367659). The reaction was performed with ABI
StepOnePlus Real-time PCR system.
Co-immuoprecipitation
Cell lysate was pre-cleared with protein A or G agarose (Roche) and
then incubated with rabbit anti-MT1-MMP antibody (ab51074,
Abcam) or goat anti-Dll1 antibody (sc-8155, Santa Cruz) for 2 h at
41C with agitation. The mixture was then incubated with protein A
or G agarose overnight at 41C with agitation. The agarose beads
were washed three times with lysis buffer and boiled in loading
buffer. The precipitated protein was analysed by immunoblot
analysis.
Immunohistochemistry
The long bone was fixed in 4% (wt/vol) paraformaldehyde,
dehydrated through serial ethanol and embedded in paraffin.
Paraffin sections were cut at a thickness of 6mm and then processed
for MT1-MMP staining.
C2C12 myotube formation assay
Either wild-type or MT1-MMP-deficient BMSCs were seeded in
24-well culture plates. When the cells became confluent, C2C12
myoblasts were plated on the BMSCs at a density of 5$103/well
and maintained in DMEM supplemented with 10% FBS. The
medium was replaced with DMEM supplemented with 2% HS after
24 h to induce myotube formation. g-Secretase inhibitor, DAPT
(Sigma), and comparable DMSO were added to selected cultures.
The medium was replaced every 3–4 days. Myotube formation was
monitored after 2 weeks.
In vitro lymphocyte development assay
Either wild-type or MT1-MMP-deficient BMSCs were seeded in 24-
well culture plates. When the cells became confluent, sorted lineage-
negative Sca1þcKitþ HPCs from adult mice total bone marrow were
plated on top of the BMSCs at a density of 4$103 and maintained in
RPMI 1640 supplemented with 10% FBS, 2mM L-glutamine, 1mM
sodium pyruvate, 2$10"5M 2-ME and 5ng/ml Flt-3L and IL-7
(R&D). g-Secretase inhibitor, DAPT, and comparable DMSO were
added to selected cultures. Lymphocyte commitment from HPCs was
analysed by flow cytometry analysis at selected time points.
In vivo DAPT treatment
DAPT was dissolved in 90% corn oil in ethanol and administrated
subcutaneously at a dose of 100mg/kg body weight, daily for 3 days
in a week (Hellstrom et al, 2007; Maeda et al, 2007). The mice were
treated for 4 weeks before they were sacrificed for analysis.
Mass spectrometry and Edman degradation
The polypeptide of mouse Dll1 (516QFLLPEPPPGPMVVDLSERH-
MESQGGPFP) was synthesized (GL Biochem) and incubated with
recombinant catalytic domain of MT1-MMP (BML-SE259) in the
digestion buffer composed of 50mM Tris–HCl (pH 7.5), 50mM
NaCl, 10mM CaCl2. After incubation for 16 h at 37
oC, the reaction
products were analysed by mass spectrometry using an ABI4800
MALDI TOF/TOFTM Analyzer. To determine the N-terminal
sequence of Dll1-CTF, the Flag-tagged fragment was purified from
293 cells overexpressing MT1-MMP and Dll1 using flag purification
kit (CELLMM2, Sigma), blotted onto the PVDF membrane and then
processed to Edman degradation (The Chinese University of Hong
Kong, HKSAR).
Statistical analysis
Statistical significance was identified with Student’s t-test or
one-way ANOVA. P-values of o0.05 were considered statistically
significant.
Supplementary data
Supplementary data are available at The EMBO Journal Online
(http://www.embojournal.org).
Acknowledgements
We thank Maggie Chow for proofreading of the manuscript,
S Artavanis-Tsakonas (Harvard Medical School) for human Notch1
cDNA and YY Lui for technical assistance in flow cytometry. This
work was supported by Research Grant Council of Hong Kong
(HKU7513/03M, G_HK027/06, HKU781808M, HKU3/07C), the CRCG
fund (201007176204), the National Science Foundation of China
(Hong Kong/Macau Young Scholar Scheme), and grants fromMinistry
of Science and Technology of CHINA (973 Projects 2007CB50740,
2011CB964700), the UGC AoE Program for ‘Developmental Genomics
and Skeletal Research’ and Deutsche Forschungsgemeinschaft through
SFB 829 (to CM). Emma Campbell, Freelance Medical Editor, UK,
provided editing assistance.
Author contributions: GJ performed most of the experiments.
GJ, KMC and KJ made the conditional MT1-MMP-deficient mice.
FZ, HLW, BL, XL and DL helped with some experiments. GJ, KC, CM
and ZZ analysed the data. GJ and ZZ prepared the manuscript.
Conflict of interest
The authors declare that they have no conflict of interest.
References
Apte SS, Fukai N, Beier DR, Olsen BR (1997) The matrix metallo-
proteinase-14 (MMP-14) gene is structurally distinct from other
MMP genes and is co-expressed with the TIMP-2 gene during
mouse embryogenesis. J Biol Chem 272: 25511–25517
MT1-MMP cleaves Dll1 to regulate Notch signalling
G Jin et al
&2011 European Molecular Biology Organization The EMBO Journal VOL 00 | NO 00 | 2011 11
Artavanis-Tsakonas S, Rand MD, Lake RJ (1999) Notch signaling:
cell fate control and signal integration in development. Science
284: 770–776
Bray SJ (2006) Notch signalling: a simple pathway becomes
complex. Nat Rev Mol Cell Biol 7: 678–689
Brou C, Logeat F, Gupta N, Bessia C, LeBail O, Doedens JR, Cumano
A, Roux P, Black RA, Israel A (2000) A novel proteolytic cleavage
involved in Notch signaling: the role of the disintegrin-metallo-
protease TACE. Mol Cell 5: 207–216
Burns CE, Traver D, Mayhall E, Shepard JL, Zon LI (2005)
Hematopoietic stem cell fate is established by the Notch-Runx
pathway. Genes Dev 19: 2331–2342
Chun TH, Hotary KB, Sabeh F, Saltiel AR, Allen ED, Weiss SJ (2006)
A pericellular collagenase directs the 3-dimensional development
of white adipose tissue. Cell 125: 577–591
Conlon RA, Reaume AG, Rossant J (1995) Notch1 is required for
the coordinate segmentation of somites. Development 121:
1533–1545
Dyczynska E, Sun D, Yi H, Sehara-Fujisawa A, Blobel CP,
Zolkiewska A (2007) Proteolytic processing of delta-like 1 by
ADAM proteases. J Biol Chem 282: 436–444
Gaiano N, Nye JS, Fishell G (2000) Radial glial identity is promoted
by Notch1 signaling in the murine forebrain. Neuron 26: 395–404
Han H, Tanigaki K, Yamamoto N, Kuroda K, Yoshimoto M, Nakahata
T, Ikuta K, Honjo T (2002) Inducible gene knockout of transcrip-
tion factor recombination signal binding protein-J reveals
its essential role in T versus B lineage decision. Int Immunol
14: 637–645
Hellstrom M, Phng LK, Hofmann JJ, Wallgard E, Coultas L,
Lindblom P, Alva J, Nilsson AK, Karlsson L, Gaiano N, Yoon K,
Rossant J, Iruela-Arispe ML, Kalen M, Gerhardt H, Betsholtz C
(2007) Dll4 signalling through Notch1 regulates formation of tip
cells during angiogenesis. Nature 445: 776–780
Hilton MJ, Tu X, Wu X, Bai S, Zhao H, Kobayashi T, Kronenberg
HM, Teitelbaum SL, Ross FP, Kopan R, Long F (2008) Notch
signaling maintains bone marrow mesenchymal progenitors
by suppressing osteoblast differentiation. Nat Med 14: 306–314
Hoebeke I, De Smedt M, Van de Walle I, Reynvoet K, De Smet G,
Plum J, Leclercq G (2006) Overexpression of HES-1 is not suffi-
cient to impose T-cell differentiation on human hematopoietic
stem cells. Blood 107: 2879–2881
Hozumi K, Mailhos C, Negishi N, Hirano K, Yahata T, Ando K,
Zuklys S, Hollander GA, Shima DT, Habu S (2008) Delta-like 4
is indispensable in thymic environment specific for T cell devel-
opment. J Exp Med 205: 2507–2513
Huppert SS, Le A, Schroeter EH, Mumm JS, Saxena MT, Milner LA,
Kopan R (2000) Embryonic lethality in mice homozygous for a
processing-deficient allele of Notch1. Nature 405: 966–970
Jaleco AC, Neves H, Hooijberg E, Gameiro P, Clode N, Haury M,
Henrique D, Parreira L (2001) Differential effects of Notch
ligands Delta-1 and Jagged-1 in human lymphoid differentiation.
J Exp Med 194: 991–1002
Jarriault S, Brou C, Logeat F, Schroeter EH, Kopan R, Israel A
(1995) Signalling downstream of activated mammalian Notch.
Nature 377: 355–358
Karanu FN, Murdoch B, Gallacher L, Wu DM, Koremoto M,
Sakano S, Bhatia M (2000) The notch ligand jagged-1 represents
a novel growth factor of human hematopoietic stem cells.
J Exp Med 192: 1365–1372
Karanu FN, Murdoch B, Miyabayashi T, Ohno M, Koremoto M,
Gallacher L, Wu D, Itoh A, Sakano S, Bhatia M (2001) Human
homologues of Delta-1 and Delta-4 function as mitogenic regula-
tors of primitive human hematopoietic cells. Blood 97: 1960–1967
Kawamata S, Du C, Li K, Lavau C (2002) Overexpression of the
Notch target genes Hes in vivo induces lymphoid and myeloid
alterations. Oncogene 21: 3855–3863
Kiel MJ, Yilmaz OH, Iwashita T, Yilmaz OH, Terhorst C, Morrison SJ
(2005) SLAM family receptors distinguish hematopoietic stem
and progenitor cells and reveal endothelial niches for stem cells.
Cell 121: 1109–1121
Kinoh H, Sato H, Tsunezuka Y, Takino T, Kawashima A, Okada Y,
Seiki M (1996) MT-MMP, the cell surface activator of proMMP-2
(pro-gelatinase A), is expressed with its substrate in mouse tissue
during embryogenesis. J Cell Sci 109(Part 5): 953–959
Koch U, Fiorini E, Benedito R, Besseyrias V, Schuster-Gossler K,
Pierres M, Manley NR, Duarte A, Macdonald HR, Radtke F (2008)
Delta-like 4 is the essential, nonredundant ligand for Notch1
during thymic T cell lineage commitment. J Exp Med 205:
2515–2523
Krebs LT, Xue Y, Norton CR, Shutter JR, Maguire M, Sundberg JP,
Gallahan D, Closson V, Kitajewski J, Callahan R, Smith GH,
Stark KL, Gridley T (2000) Notch signaling is essential for
vascular morphogenesis in mice. Genes Dev 14: 1343–1352
Kumano K, Chiba S, Kunisato A, Sata M, Saito T, Nakagami-
Yamaguchi E, Yamaguchi T, Masuda S, Shimizu K, Takahashi T,
Ogawa S, Hamada Y, Hirai H (2003) Notch1 but not Notch2 is
essential for generating hematopoietic stem cells from endothelial
cells. Immunity 18: 699–711
Lehar SM, Dooley J, Farr AG, Bevan MJ (2005) Notch ligands Delta
1 and Jagged1 transmit distinct signals to T-cell precursors.
Blood 105: 1440–1447
Lehti K, Allen E, Birkedal-Hansen H, Holmbeck K, Miyake Y,
Chun TH, Weiss SJ (2005) An MT1-MMP-PDGF receptor-beta
axis regulates mural cell investment of the microvasculature.
Genes Dev 19: 979–991
Lehti K, Rose NF, Valavaara S, Weiss SJ, Keski-Oja J (2009) MT1-
MMP promotes vascular smooth muscle dedifferentiation
through LRP1 processing. J Cell Sci 122: 126–135
Logan M, Martin JF, Nagy A, Lobe C, Olson EN, Tabin CJ (2002)
Expression of Cre Recombinase in the developing mouse limb
bud driven by a Prxl enhancer. Genesis 33: 77–80
Maeda T, Merghoub T, Hobbs RM, Dong L, Maeda M, Zakrzewski J,
van den Brink MR, Zelent A, Shigematsu H, Akashi K,
Teruya-Feldstein J, Cattoretti G, Pandolfi PP (2007) Regulation
of B versus T lymphoid lineage fate decision by the
proto-oncogene LRF. Science 316: 860–866
Maillard I, Koch U, Dumortier A, Shestova O, Xu L, Sai H, Pross SE,
Aster JC, Bhandoola A, Radtke F, Pear WS (2008) Canonical
notch signaling is dispensable for the maintenance of adult
hematopoietic stem cells. Cell Stem Cell 2: 356–366
Masuzawa T, Miyaura C, Onoe Y, Kusano K, Ohta H, Nozawa S,
Suda T (1994) Estrogen deficiency stimulates B lymphopoiesis in
mouse bone marrow. J Clin Invest 94: 1090–1097
Morrison SJ, Perez SE, Qiao Z, Verdi JM, Hicks C, Weinmaster G,
Anderson DJ (2000) Transient Notch activation initiates an
irreversible switch from neurogenesis to gliogenesis by neural
crest stem cells. Cell 101: 499–510
Morrow D, Guha S, Sweeney C, Birney Y, Walshe T, O’Brien C,
Walls D, Redmond EM, Cahill PA (2008) Notch and vascular
smooth muscle cell phenotype. Circ Res 103: 1370–1382
Mumm JS, Schroeter EH, Saxena MT, Griesemer A, Tian X, Pan DJ,
Ray WJ, Kopan R (2000) A ligand-induced extracellular cleavage
regulates gamma-secretase-like proteolytic activation of Notch1.
Mol Cell 5: 197–206
Muraguchi T, Takegami Y, Ohtsuka T, Kitajima S, Chandana EP,
Omura A, Miki T, Takahashi R, Matsumoto N, Ludwig A, Noda M,
Takahashi C (2007) RECK modulates Notch signaling during
cortical neurogenesis by regulating ADAM10 activity. Nat
Neurosci 10: 838–845
Nagasawa T (2006) Microenvironmental niches in the bone marrow
required for B-cell development. Nat Rev 6: 107–116
Nofziger D, Miyamoto A, Lyons KM, Weinmaster G (1999) Notch
signaling imposes two distinct blocks in the differentiation
of C2C12 myoblasts. Development 126: 1689–1702
Peister A, Mellad JA, Larson BL, Hall BM, Gibson LF, Prockop DJ
(2004) Adult stem cells from bone marrow (MSCs) isolated
from different strains of inbred mice vary in surface epitopes,
rates of proliferation, and differentiation potential. Blood 103:
1662–1668
Pui JC, Allman D, Xu L, DeRocco S, Karnell FG, Bakkour S, Lee JY,
Kadesch T, Hardy RR, Aster JC, Pear WS (1999) Notch1 expres-
sion in early lymphopoiesis influences B versus T lineage deter-
mination. Immunity 11: 299–308
Radtke F, Wilson A, MacDonald HR (2004) Notch signaling in T- and
B-cell development. Curr Opin Immunol 16: 174–179
Radtke F, Wilson A, Stark G, Bauer M, van Meerwijk J,
MacDonald HR, Aguet M (1999) Deficient T cell fate specification
in mice with an induced inactivation of Notch1. Immunity 10:
547–558
Robert-Moreno A, Guiu J, Ruiz-Herguido C, Lopez ME, Ingles-
Esteve J, Riera L, Tipping A, Enver T, Dzierzak E, Gridley T,
Espinosa L, Bigas A (2008) Impaired embryonic haematopoiesis
yet normal arterial development in the absence of the Notch
ligand Jagged1. EMBO J 27: 1886–1895
MT1-MMP cleaves Dll1 to regulate Notch signalling
G Jin et al
The EMBO Journal VOL 00 | NO 00 | 2011 &2011 European Molecular Biology Organization12
Sato H, Takino T, Okada Y, Cao J, Shinagawa A, Yamamoto E,
Seiki M (1994) A matrix metalloproteinase expressed on the
surface of invasive tumour cells. Nature 370: 61–65
Schmitt TM, Ciofani M, Petrie HT, Zuniga-Pflucker JC (2004)
Maintenance of T cell specification and differentiation requires
recurrent notch receptor-ligand interactions. J Exp Med 200: 469–479
Schmitt TM, Zuniga-Pflucker JC (2002) Induction of T cell develop-
ment from hematopoietic progenitor cells by delta-like-1 in vitro.
Immunity 17: 749–756
Schroeter EH, Kisslinger JA, Kopan R (1998) Notch-1 signalling
requires ligand-induced proteolytic release of intracellular
domain. Nature 393: 382–386
Seiki M, Yana I (2003) Roles of pericellular proteolysis by membrane
type-1 matrix metalloproteinase in cancer invasion and angiogen-
esis. Cancer Sci 94: 569–574
Shawber C, Nofziger D, Hsieh JJ, Lindsell C, Bogler O, Hayward D,
Weinmaster G (1996) Notch signaling inhibits muscle cell differ-
entiation through a CBF1-independent pathway. Development
122: 3765–3773
Six E, Ndiaye D, Laabi Y, Brou C, Gupta-Rossi N, Israel A, Logeat F
(2003) The Notch ligand Delta1 is sequentially cleaved by an
ADAM protease and gamma-secretase. Proc Natl Acad Sci USA
100: 7638–7643
Stier S, Cheng T, Dombkowski D, Carlesso N, Scadden DT (2002)
Notch1 activation increases hematopoietic stem cell self-renewal
in vivo and favors lymphoid over myeloid lineage outcome.
Blood 99: 2369–2378
Sugiyama T, Kohara H, Noda M, Nagasawa T (2006) Maintenance of
the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine
signaling in bone marrow stromal cell niches. Immunity 25: 977–988
Suzuki T, Yokoyama Y, Kumano K, Takanashi M, Kozuma S,
Takato T, Nakahata T, Nishikawa M, Sakano S, Kurokawa M,
Ogawa S, Chiba S (2006) Highly efficient ex vivo expansion
of human hematopoietic stem cells using Delta1-Fc chimeric
protein. Stem Cells 24: 2456–2465
Tokoyoda K, Egawa T, Sugiyama T, Choi BI, Nagasawa T (2004)
Cellular niches controlling B lymphocyte behavior within bone
marrow during development. Immunity 20: 707–718
Varnum-Finney B, Purton LE, Yu M, Brashem-Stein C, Flowers D,
Staats S, Moore KA, Le Roux I, Mann R, Gray G, Artavanis-
Tsakonas S, Bernstein ID (1998) The Notch ligand, Jagged-1,
influences the development of primitive hematopoietic precursor
cells. Blood 91: 4084–4091
Wilson A, MacDonald HR, Radtke F (2001) Notch 1-deficient
common lymphoid precursors adopt a B cell fate in the thymus.
J Exp Med 194: 1003–1012
Wu L, Aster JC, Blacklow SC, Lake R, Artavanis-Tsakonas S,
Griffin JD (2000) MAML1, a human homologue of Drosophila
mastermind, is a transcriptional co-activator for NOTCH
receptors. Nat Genet 26: 484–489
Yana I, Sagara H, Takaki S, Takatsu K, Nakamura K, Nakao K,
Katsuki M, Taniguchi SI, Aoki T, Sato H, Weiss SJ, Seiki M (2007)
Crosstalk between neovessels and mural cells directs the
site-specific expression of MT1-MMP to endothelial tip cells.
J Cell Sci 120(Part 9): 1607–1614
Zhou Z, Apte SS, Soininen R, Cao R, Baaklini GY, Rauser RW,
Wang J, Cao Y, Tryggvason K (2000) Impaired endochondral
ossification and angiogenesis in mice deficient in membrane-
type matrix metalloproteinase I. Proc Natl Acad Sci USA 97:
4052–4057
MT1-MMP cleaves Dll1 to regulate Notch signalling
G Jin et al
&2011 European Molecular Biology Organization The EMBO Journal VOL 00 | NO 00 | 2011 13
